Endometrial cancer is one of the few cancers for which mortality is still increasing. A lack of treatment options remains a major challenge, particularly for some subtypes of the disease. GZD824, also known as olverembatinib, is a multi-kinase inhibitor previously investigated in clinical trials for chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia as a BCR-ABL inhibitor. This study aimed to investigate the pre-clinical efficacy of GZD824 for the treatment of EC.
| Authors | Liu, D; Glubb, D; O'Mara, T; Ford, CE |
|---|---|
| Journal | Cancer medicine |
| Pages | e70531 |
| Volume | 14 |
| Date | 1/01/2025 |
| Grant ID | APP1173170 | National Health and Medical Research Council; UNSW Med & Health ECAN seed grant |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1002/cam4.70531 |